WALTHAM, Mass., April 6, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that the company has initiated a Phase 1b/2a study of its dual-mechanism, second-generation vascular disrupting agent (VDA), OXi4503, in patients with solid tumors with hepatic involvement.
